CCRM
Min S. is an experienced finance professional with a robust background in corporate accounting and finance. Currently serving as the Corporate Accounting Manager for Operations Controllership at CCRM since December 2020, Min has previously held significant roles including Corporate Finance Lead at Dalton Pharma Services and Controller at SIWM & TSI Network. Prior experience at McKesson Canada includes positions as Corporate Accounting Supervisor in both RBS and Drug Trading. Min S. holds a CPA, CGA designation from CPA Ontario and a Bachelor of Business Administration from Pontifícia Universidade Católica de São Paulo.
This person is not in any teams
This person is not in any offices
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.